ACCESS Newswire

Phyto Extractions Inc.

15.7.2021 15:04:07 CEST | ACCESS Newswire | Press release

Share
Phyto Extractions Secures Biomass Supply Agreement

LANGLEY, BC / ACCESSWIRE / July 15, 2021 / Phyto Extractions Inc. (formerly, Adastra Labs Holdings Ltd.) (CSE:XTRX)(Frankfurt:D2EP) ("Phyto Extractions™, "Phyto" or the "Company") has secured a supply agreement for dried cannabis with a major Canadian License Holder. The supply agreement will provide upwards of 12,000 kgs of dried cannabis biomass over six months.

Phyto Extractions Inc.'s, wholly owned Health Canada licensed subsidiary, Adastra Labs Inc. will leverage its agricultural scale extraction, formulation and product fulfillment capabilities to produce an estimated 1,500 kg of high-value cannabis concentrates. These concentrates will be incorporated into consumer-packaged goods under the Phyto Extractions™ brand, for distribution across Canada. Additionally, the scientific team at Phyto will make use of their industry-leading cryogenic ethanol and hydrocarbon extraction systems to efficiently produce distillate, with over 90% THC, shatter, full-spectrum shatter vaporizer cartridges and other hydrocarbon derivative products. These products will generate up to $74,985,000 in retail sales across Canada. (BC Cannabis Stores). Fulfillment of this supply agreement will represent 1/3 of the company's extraction capacity, allowing Phyto Extractions™ to continue to expand its operations and product lines with new brands and partners.

Phyto will be able to reduce its produced per gram cost by over 25% by acquiring the low-cost input cannabis. These savings will then be passed along to consumers. Aggressive price reductions at retail locations will facilitate substantial expansion to major Canadian cannabis markets, while consistent supply will support continual growth within existing product offerings.

"The security of supply at such an attractive price will allow Phyto Extractions™ to grow with increasing demand of it's already popular SKUs and expand its hydrocarbon extraction product offerings across the country at extremely competitive prices for retailers and consumers alike," said Donald Dinsmore, COO.

To learn more about Phyto Extractions™ and the team, please watch the following video:

To view this piece of content from www.youtube.com, please give your consent at the top of this page.To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

https://youtu.be/pXWgR2MqZDY

About Phyto Extractions™

Phyto Extractions™ is an agricultural-scale cannabis extraction, distillation and product manufacturer located in Langley, BC at its co-located Health Canada Licensed Standard Processing (extraction and products, no cultivation), Sales (extracts, topicals, and edibles), and R&D through Adastra Labs Inc. and Analytical Testing Laboratory through Chemia Analytics Inc.

ON BEHALF OF THE BOARD PHYTO EXTRACTIONS INC. (CSE: XTRX)
Contact: Michael Forbes, President, CEO & Director (Chairman)
Phone: 778-715-5011
Email: michael@phytoextractions.ca

Forward-Looking Information:

This news release includes forward-looking information within the meaning of Canadian securities legislation, concerning the business of the Company. Forward-looking information is based on certain key expectations and assumptions made by the management of the Company. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Forward-looking information in this news release includes statements with respect of the proposed name change, proposed consolidation, the closing of the private placement and the use of proceeds thereof. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward looking information, including: (i) adverse market conditions; (ii) risks inherent in the cannabis extraction sector in general; (iii) inability to close the private placement for any reason, or in the amounts expected by the Company; and (iv) other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements. The CSE has not reviewed or approved of any contents of this news release.

SOURCE: Phyto Extractions Inc.



View source version on accesswire.com:
https://www.accesswire.com/655670/Phyto-Extractions-Secures-Biomass-Supply-Agreement

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Akkodis Completes the Acquisition of SOGECLAIR's Engineering Activities, Strengthening Its Aerospace & Defense Leadership1.10.2026 17:30:00 CEST | Press release

ZÜRICH, SWITZERLAND / ACCESS Newswire / October 1, 2026 / Akkodis, a global digital engineering consulting company, today announced the completion of its acquisition of SOGECLAIR's engineering activities dedicated to Airbus; SOGECLAIR is a leading international engineering and technology company specializing in aerospace, defense and mobility. Image: Akkodis completes acquisition of SOGECLAIR's engineering activities Source: Akkodis The transaction marks a significant milestone in Akkodis' strategy to strengthen its position in the aerospace and defense sector by expanding its capabilities in aerostructures, cabin engineering and manufacturing engineering. It further enhances Akkodis' ability to support customers across the entire product lifecycle, from design and engineering through industrialization and in-service support. With the integration of SOGECLAIR's engineering activities dedicated to Airbus, Akkodis reinforces its position as one of the leading engineering partners to the

Anew Climate Expands European Forest Carbon Portfolio Through Ten-Year Agreement with Sweden's EKEN1.10.2026 15:00:00 CEST | Press release

HOUSTON, TX / ACCESS Newswire / October 1, 2026 / Anew Climate (Anew), one of the world's largest developers and marketers of carbon credits, announced a ten-year agreement with EKEN Financing Value Added Forestry (EKEN) to bring Swedish improved forest management (IFM) credits to corporate buyers worldwide. The agreement extends Anew's European forest carbon portfolio, which it maintains alongside millions of acres of managed forestland across North America. Under the collaboration, Anew will serve as the exclusive commercialization partner for credits generated from projects developed by EKEN, handling purchaser engagements, structuring, and portfolio integration for corporate buyers in Europe and internationally. EKEN is preparing the project for development under VM0045, Verra's methodology for improved forest management using dynamic matched baselines from national forest inventories. While many conventional forest carbon baselines rest on a projection of what a landowner would hy

Karbon‑X (OTCQB:KARX) Reports Record Fiscal 2026 Revenue of $55.9 Million as Company Scales Global Carbon Market Operations1.10.2026 14:30:00 CEST | Press release

CALGARY, AB / ACCESS Newswire / October 1, 2026 / Karbon‑X Corp. (OTCQB:KARX) ("Karbon‑X" or the "Company"), a vertically integrated climate solutions company operating across global carbon markets, today reported financial and operational results for the fiscal year ended May 31, 2026, reflecting a significant increase in operating scale across its carbon credit trading and project development activities. Karbon‑X generated record fiscal 2026 revenue of $55.9 million, compared with $3.16 million in fiscal 2025, representing an increase of approximately 1,670% year over year. Gross profit was $0.86 million, compared with $0.80 million in the prior year. Fiscal 2026 results reflected a shift in revenue mix toward high-volume, lower-margin trading activity as Karbon‑X completed its first full year of large-scale carbon credit trading. "Fiscal 2026 moved Karbon-X into a new stage of commercial growth," said Chad Clovis, Chief Executive Officer of Karbon-X. "Revenue reached nearly eighteen

Surmodics Acquires Alta Biomed Business, Expanding Hemocompatible Surface Technology and Analytical Testing Capabilities1.10.2026 14:00:00 CEST | Press release

HORSHAM, PA / ACCESS Newswire / October 1, 2026 / Surmodics Inc., a leading provider of surface technologies and performance coatings for the medical device industry, today announced that it has acquired the business of Alta Biomed, a Carlsbad, California-based medical device coating and testing services company specializing in surface technologies for vascular and other medical devices. The acquisition is a strategic addition to Surmodics' growing portfolio of hemocompatible and biocompatible surface technologies. It brings Alta Biomed's proprietary PzF™ thin-film surface modification technology to Surmodics, adding an established anti-thrombotic, anti-inflammatory and pro-healing option that joins Surmodics' existing hemocompatible portfolio. "As medical device innovation advances in neuromodulation, brain-computer interfaces, neurovascular, structural heart, and venous and arterial technologies, engineers and scientists need a broader range of surface technology options to address i

PharmaNest and Mediar Therapeutics Collaborate to Quantify ECM and Fibrosis Remodeling in the EncompaSSc Phase 2 Trial of MTX-474 in Diffuse Cutaneous Systemic Sclerosis30.9.2026 19:00:00 CEST | Press release

PRINCETON, NJ / ACCESS Newswire / September 30, 2026 / PharmaNest, Inc. an AI-enabled digital pathology company specializing in the quantitative and spatial characterization of fibrosis and Mediar Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapies to halt and reverse fibrosis, today announced a collaboration to integrate advanced digital pathology into Mediar's ongoing EncompaSSc Phase 2 clinical trial of MTX-474 in patients with diffuse cutaneous systemic sclerosis (dcSSc). MTX-474 is a first-in-class human IgG1 monoclonal antibody designed to neutralize EphrinB2 signaling, a pathway implicated in myofibroblast activation, extracellular matrix (ECM) deposition and tissue remodeling known to drive fibrosis in SSc. The randomized, double-blind, placebo-controlled EncompaSSc Phase 2 study is evaluating the safety and efficacy of MTX-474 in patients with dcSSc. Under the collaboration, PharmaNest will apply its FibroNest™ AI-enabled digital path

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye